Hyperglycemia Acutely Increases Cytosolic Reactive Oxygen Species via O-linked GlcNAcylation and CaMKII Activation in Mouse Ventricular Myocytes
Shan Lu,Zhandi Liao,Xiyuan Lu,Dörthe M. Katschinski,Mark Mercola,Ju Chen,Joan Heller Brown,Jeffery D. Molkentin,Julie Bossuyt,Donald M. Bers,Shan Lu Zhandi Liao Xiyuan Lu Dörthe M Katschinski Mark Mercola Ju Chen Joan Heller Brown Jeffery D. Molkentin Julie Bossuyt Donald M Bers Pharmacology,University of California,Davis,UNITED STATES Pharmacology,First Hospital of Soochow University,CHINA Georg August University Göttingen Cardiovascular Institute,Stanford University,UNITED STATES Medicine,University of California San Diego,UNITED STATES Pharmacology,University of California San Diego,UNITED STATES Pediatrics,Cincinnati Children's Hospital Medical Center,UNITED STATES
DOI: https://doi.org/10.1161/CIRCRESAHA.119.316288
IF: 23.213
2020-03-07
Circulation Research
Abstract:Rationale: Diabetes mellitus (DM) is a complex, multisystem disease, affecting large populations worldwide. Chronic CaMKII activation may occur in DM and be arrhythmogenic. Diabetic hyperglycemia was shown to activate CaMKII by (1) O-linked attachment of N-acetylglucosamine (O-GlcNAc) at S280 leading to arrhythmia and (2) a reactive-oxygen species (ROS) mediated oxidation of CaMKII, that can increase post-infarction mortality. Objective: To test whether high extracellular [glucose] (Hi-Glu) promotes ventricular myocyte ROS generation and the role played by CaMKII. Methods and Results: We tested how extracellular Hi-Glu influences ROS production in adult ventricular myocytes, using H2DCFDA and genetically targeted Grx-roGFP2 redox sensors. Hi-Glu (30 mmol/L) significantly increased the rate of ROS generation, an effect prevented in myocytes pretreated with CaMKII inhibitor KN-93 or from either global or cardiac specific CaMKIIδ knockout mice. CaMKII knockout or inhibition also prevented Hi-Glu induced sarcoplasmic reticulum (SR) Ca 2+ release events (Ca 2+ sparks). Thus, CaMKII activation is required for Hi-Glu induced ROS generation and SR Ca leak in cardiomyocytes. To test the involvement of O-GlcNAc-CaMKII pathway, we inhibited GlcNAcylation removal by Thiamet G (Thm-G), which mimicked the Hi-Glu-induced ROS production. Conversely, inhibition of GlcNAcylation (OSMI-1) prevented ROS induction in response to either Hi-Glu or Thm-G. Moreover, in a CRSPR-based knock-in mouse in which the functional GlcNAcylation site on CaMKIIδ was ablated (S280A) neither Hi-Glu nor Thm-G induced myocyte ROS generation. So CaMKIIδ-S280 is required for the Hi-Glu-induced (and GlcNAc-dependent) ROS production. To identify the ROS source(s), we used different inhibitors of NOX2 (Gp91ds-tat peptide), NOX4 (GKT137831), mitochondrial ROS (Mito-Tempo) and NOS pathway inhibitors (L-NAME, L-NIO and L-NPA). Only NOX2 inhibition or KO prevented Hi-Glu/Thm-G induced ROS generation. Conclusions: Diabetic hyperglycemia induces acute cardiac myocyte ROS production by NOX2 that requires O-GlcNAcylation of CaMKIIδ at S280. This novel ROS induction may exacerbate pathological consequences of diabetic hyperglycemia.
cardiac & cardiovascular systems,peripheral vascular disease,hematology